ArticleFrontiers in microbiology2025
Mapping cross-reactive residues in the G-H loop of foot-and-mouth disease virus: insights for serotype-specific design.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Foot-and-mouth disease virus (FMDV) has a hypervariable G-H loop region within the VP1 capsid protein. This structure is associated with virus neutralisation and contains the virus attachment motif (RGD) which binds to the cellular integrin receptor facilitating virus entry for all seven FMDV serotypes. Methods: Six monoclonal antibodies (Mabs) were tested against 10 peptides representing the wild-type G-H loops of serotypes O, A, SAT1, and SAT2. D9 and B2 Mabs were raised against serotype O and tested against three more sets of peptides: (1) nine overlapping peptides with one amino acid difference, (2) alanine scanning peptide, both for O1K strain and (3) four mutated peptides one for A22 and three for SAT2 strains in the enzyme-linked immunosorbent assay format with correlation to virus neutralisation test. Results: The D9 Mab was bound to peptides corresponding to the G-H loops of serotype O, A, and SAT1 strains, but only neutralised serotype O and SAT1 strains in the virus neutralisation test. The B2 Mab is also bound to serotype O and SAT1 but only neutralised serotype O. Using a set of overlapping peptides, the binding region for the D9 Mab was confirmed as amino acid positions 144, 147 and 148. An additional critical amino acid residue at position 145R was identified using a set of alanine scanning peptides. The binding region for B2 Mab appears to be upstream of RGD as B2 showed lower binding to peptides lacking the first three amino acids of the GH-loop peptides. These critical amino acids were further confirmed by designing modified SAT2 and A peptides at these positions, which led to a significant improvement in the binding ability of D9 but not B2. Conclusion: These findings help to map cross-reactive epitopes within the G-H loop which may contribute to the inter-serotypic cross-reactivity observed in diagnostic serological assays giving insights that motivate the design of custom peptides that have improved serotype specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.